請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/39496
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳玉怜 | |
dc.contributor.author | Wan-Ju Hsieh | en |
dc.contributor.author | 謝琬汝 | zh_TW |
dc.date.accessioned | 2021-06-13T17:30:00Z | - |
dc.date.available | 2016-10-07 | |
dc.date.copyright | 2011-10-07 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-07-12 | |
dc.identifier.citation | Arakawa Y, Sakaki H. Multidimensional quantum well laser and temperature dependent of its threshold current. Appl Phys Lett. 1982; 40: 939-941
Briley-Saebo K, Bjørnerud A, Grant D, Ahlstrom H, Berg T, Kindberg GM. Hepatic cellular distribution and degradation of iron oxide nanoparticles following single intravenous injection in rats: implications for magnetic resonance imaging. Cell Tissue Res. 2004; 316: 315-323. Cao Y. Antiangiogenic cancer therapy. Seminars in Cancer Biology .2004; 14: 139–145. Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Gadolinium (III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. Chem Rev. 1999; 99: 2293-2352. Carson-Walter EB, Watkins DN, Nanda A, Vogelstein B, Kinzler KW, St Croix B. Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res. 2001; 61: 6649-6655. Cavicchi RE, Silsbee RH. Coulomb suppression of tunneling rate from small metal particles. Phys. Rev. Lett.1984; 52: 1453–1456 Cegnar M, Premzl A, Zavasnik-Bergant V, Kristl J, Kos J. Poly(lactide-co-glycolide) nanoparticles as a carrier system for delivering cysteine protease inhibitor cystatin into tumor cells. Exp Cell Res. 2004; 301: 223-231. Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008; 14: 1310-1316. Chouly C, Pouliquen D, Lucet I, Jeune JJ, Jallet P. Development of superparamagnetic nanoparticles for MRI: effect of particle size, charge and surface nature on biodistribution. J Microencapsul. 1996; 13: 245-255. Collingridge DR, Carroll VA, Glaser M, Aboagye EO, Osman S, Hutchinson OC, Barthel H, Luthra SK, Brady F, Bicknell R, Price P, Harris AL. The development of [124I] iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Res. 2002; 62: 5912-5919. Corot C, Robert P, Idée JM, Port M. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev. 2006; 58: 1471-1504. Daram SR, Cortese CM, Bastani B. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review. Am J Kidney Dis. 2005; 46: 754-759. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res. 2000; 60: 1388-1393. Ellis LM, Takahashi Y, Liu W, Shaheen RM. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. Oncologist. 2000; 5:11-15. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003; 9: 669-676. Fletcher F, London E. Intravenous iron. Br Med J. 1954; 84. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285: 1182-1186. Folkman J. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. Vol 2. 7th ed. Greene FL, Stewart AK, Norton HJ. A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients. Ann Surg. 2002; 236: 416–421. Gupta AK, Curtis AS. Surface modified superparamagnetic nanoparticles for drug delivery: interaction studies with human fibroblasts in culture. J Mater Sci Mater Med. 2004; 15: 493-496. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials. 2005; 26: 3995-4021. Hambley TW, Hait WN. Is anticancer drug development heading in the right direction? Cancer Res. 2009; 69: 1259-1262. Hanahan D, Weinberg RA. The Hallmarks of Cancer. Cell. 2000; 7: 57-70. Harris AL. Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer. 2002; 2: 38-47. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol.2005; 23: 1011-1027. Hifumi H, Yamaoka S, Tanimoto A, Citterio D, Suzuki K. Gadolinium-based hybrid nanoparticles as a positive MR contrast agent. J Am Chem Soc. 2006; 128: 15090-15091. Hilger I, Hergt R, Kaiser WA. Use of magnetic nanoparticle heating in the treatment of breast cancer. IEE Proc Nanobiotechnol. 2005; 152: 33-39. Hlatky L, Tsionou C, Hahnfeldt P, Coleman CN. Mammary fibroblasts may influence breast tumor angiogenesis via hypoxia-induced vascular endothelial growth factor up-regulation and protein expression. Cancer Res. 1994; 54: 6083-6086. Holten-Andersen MN, Christensen IJ, Nielsen HJ, Stephens RW, Jensen V, Nielsen OH, Sørensen S, Overgaard J, Lilja H, Harris A, Murphy G, Brünner N. Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res. 2002; 8: 156-164. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol. 1991; 5: 1806-1814. Huang X, Jain PK, El-Sayed IH, El-Sayed MA. Plasmonic photothermal therapy (PPTT) using gold nanoparticles. Lasers Med Sci. 2008; 23: 217-228. Huber DL. Synthesis, properties, and applications of iron nanoparticles. Small. 2005; 1: 482-501. Iijima S. Helical microtubules of graphitic carbon. Nature.1991; 354: 56-58. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today. 2006; 11: 812-818. Jain RK. Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng. 1999; 1: 241-263. Josephson L, Tung CH, Moore A, Weissleder R. High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. Bioconjug Chem. 1999; 10: 186-191. Kim JH, Kim YS, Park K, Lee S, Nam HY, Min KH, Jo HG, Park JH, Choi K, Jeong SY, Park RW, Kim IS, Kim K, Kwon IC. Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. J Control Release. 2008; 127: 41-49. Koropchak JA, Sadain S, Yang X, Magnusson LE, Heybroek M, Anisimov M, Kaufman SL. Nanoparticle detection technology for chemical analysis. Anal Chem. 1999; 71: 386-394. Kruyt H .Colloid Science.1952. Larsen AK, Escargueil AE, Skladanowski A. Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Ther. 2000; 85: 217-229. LeBoit PE. What nephrogenic fibrosing dermopathy might be. Arch Dermatol. 2003; 139: 928-930. Liu Y, Miyoshi H, Nakamura M. Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int J Cancer. 2007; 120: 2527-2537. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 65: 271-284. Matuszewski L, Persigehl T, Wall A, Schwindt W, Tombach B, Fobker M, Poremba C, Ebert W, Heindel W, Bremer C. Cell tagging with clinically approved iron oxides: feasibility and effect of lipofection, particle size, and surface coating on labeling efficiency. Radiology. 2005; 235: 155-161. McBain SC, Yiu HH, Dobson J. Magnetic nanoparticles for gene and drug delivery. Int J Nanomedicine. 2008; 3: 169-180. Millauer B, Wizigmann-Voos S, Schnürch H, Martinez R, Møller NP, Risau W, Ullrich A. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell. 1993; 72: 835-846. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 2001; 53: 283-318. Morawski AM, Winter PM, Crowder KC, Caruthers SD, Fuhrhop RW, Scott MJ, Robertson JD, Abendschein DR, Lanza GM, Wickline SA. Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI. Magn Reson Med. 2004; 51: 480-486. Mornet S, Vasseur S, Grasset F, Duguet E. Magnetic nanoparticle design for medical diagnosis and therapy. J. Mater. Chem. 2004; 14: 2161-2175 Peng XH, Qian X, Mao H, Wang AY, Chen ZG, Nie S, Shin DM. Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. Int J Nanomedicine. 2008; 3: 311-321. Petri-Fink A, Chastellain M, Juillerat-Jeanneret L, Ferrari A, Hofmann H. Development of functionalized superparamagnetic iron oxide nanoparticles for interaction with human cancer cells. Biomaterials. 2005; 26: 2685-2694. Pilch H, Schlenger K, Steiner E, Brockerhoff P, Knapstein P, Vaupel P. Hypoxia-stimulated expression of angiogenic growth factors in cervical cancer cells and cervical cancer-derived fibroblasts. Int J Gynecol Cancer. 2001; 11: 137-142. Remsen LG, McCormick CI, Roman-Goldstein S, Nilaver G, Weissleder R, Bogdanov A, Hellström I, Kroll RA, Neuwelt EA. MR of carcinoma-specific monoclonal antibody conjugated to monocrystalline iron oxide nanoparticles: the potential for noninvasive diagnosis. AJNR Am J Neuroradiol. 1996; 17: 411-418. Roser M, Fischer D, Kissel T. Surface-modified biodegradable albumin nano- and microspheres. II: effect of surface charges on in vitro phagocytosis and biodistribution in rats. Eur J Pharm Biopharm. 1998; 46: 255-263. Ruoslahti E, Bhatia SN, Sailor MJ. Targeting of drugs and nanoparticles to tumors. J Cell Biol. 2010; 188: 759-768. Saeed M, Wendland MF, Engelbrecht M, Sakuma H, Higgins CB. Value of blood pool contrast agents in magnetic resonance angiography of the pelvis and lower extremities. Eur Radiol. 1998; 8: 1047-1053. Schroeder JA, Weingart C, Coras B, Hausser I, Reinhold S, Mack M, Seybold V, Vogt T, Banas B, Hofstaedter F, Krämer BK. Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease. Clin J Am Soc Nephrol. 2008; 3: 968-975. Shellock FG, Spinazzi A.MRI safety update 2008: part 1, MRI contrast agents and nephrogenic systemic fibrosis. AJR Am J Roentgenol. 2008; 191: 1129-1139. Shi X, Thomas TP, Myc LA, Kotlyar A, Baker JR Jr. Synthesis, characterization, and intracellular uptake of carboxyl-terminated poly(amidoamine) dendrimer-stabilized iron oxide nanoparticles. Phys Chem Chem Phys. 2007; 9: 5712-5720. Soker S, Fidder H, Neufeld G, Klagsbrun M. Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain. J Biol Chem. 1996; 271: 5761-5767. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Girard OM, Hanahan D, Mattrey RF, Ruoslahti E. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell. 2009; 16: 510-520. Sun C, Sze R, Zhang M. Folic acid-PEG conjugated superparamagnetic nanoparticles for targeted cellular uptake and detection by MRI. J Biomed Mater Res A. 2006; 78: 550-557. Thorek DL, Chen AK, Czupryna J, Tsourkas A. Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann Biomed Eng. 2006; 34: 23-38. Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev. 2008; 60: 1421-1434. Tiefenauer LX, Tschirky A, Kühne G, Andres RY. In vivo evaluation of magnetite nanoparticles for use as a tumor contrast agent in MRI. Magn Reson Imaging. 1996; 14: 391-402. Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol. 2003; 139: 903-906. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem. 1991; 266: 11947-11954. Toma A, Otsuji E, Kuriu Y, Okamoto K, Ichikawa D, Hagiwara A, Ito H, Nishimura T, Yamagishi H. Monoclonal antibody A7-superparamagnetic iron oxide as contrast agent of MR imaging of rectal carcinoma. Br J Cancer. 2005; 93: 131-136. van Osdol W, Fujimori K, Weinstein JN. An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a 'binding site barrier'. Cancer Res. 1991; 51: 4776-4784. Wang YX, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol. 2001; 11: 2319-2331 Weissleder R, Bogdanov A, Neuwelt A, Papisov M. Long-circulating iron oxides for MR imaging. Adv. Drug Deliv.Rev.1995; 16: 321–334. Weissleder R, Hahn PF, Stark DD, Elizondo G, Saini S, Todd LE, Wittenberg J, Ferrucci JT. Superparamagnetic iron oxide: enhanced detection of focal splenic tumors with MR imaging. Radiology. 1988; 169: 399-403. Willmann JK, Paulmurugan R, Chen K, Gheysens O, Rodriguez-Porcel M, Lutz AM, Chen IY, Chen X, Gambhir SS. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology. 2008; 246: 508-518. Yang L, Mao H, Wang YA, Cao Z, Peng X, Wang X, Duan H, Ni C, Yuan Q, Adams G, Smith MQ, Wood WC, Gao X, Nie S. Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging. Small. 2009; 5: 235-43. Yonghong N, Xuewu G, Zhicheng Z, Qiang Y. Fabrication and characterization of the plate-shaped γ-Fe2O3 nano-crystals. Chem.Mater. 2002; 14: 1048-1052. Zeng H, Dvorak HF, Mukhopadhyay D. Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) peceptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent pathways. J Biol Chem. 2001; 276: 26969-26979. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 2008; 83: 761-769. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/39496 | - |
dc.description.abstract | 磁性氧化鐵奈米粒子對生物具有低毒性、高生物降解率、可穩定存在於循環中等性質,藉由在奈米粒子表面修飾加上腫瘤標靶物質,可以用來追蹤腫瘤位置,協助診斷。血管內皮生長因子在許多不同的腫瘤中皆有高度表現,使其成為一個可行的標靶目標,因此我們針對血管內皮生長因子設計出可標靶的氧化鐵奈米粒子(vascular endothelial growth factor antibody conjugated iron oxide nanoparticles,VEGF-NP)來達到腫瘤標靶的目的。為了測試此奈米粒子在循環後到達腫瘤中的分布情形,將帶有表達VEGF的小鼠大腸癌細胞CT26植入BALB/c小鼠,再經由頸靜脈注射給予VEGF-NP,由核磁共振(magnetic resonance imaging,MRI) 做觀察。結果顯示在給予VEGF-NP的組別可顯著的縮短T2遲緩時間使得T*2訊號降低,在MRI下呈黑色顯影。進一步以普魯士藍染色法,其實驗結果顯示,給予VEGF-NP的組別,在腫瘤組織切片中有強烈的藍色反應,表示有大量的VEGF-NP聚積在腫瘤中。另外在穿透式電子顯微鏡結果中也發現,給予VEGF-NP的組別,腫瘤細胞或細胞外基質也可觀察到奈米粒子。目前我們的研究結果顯示,VEGF-NP經過體循環後,不易被網狀內皮系統(reticuloendothlial system)清除,仍可以大量聚集到腫瘤組織中,顯著增強MRI的造影,以利判別腫瘤位置,未來可作為一個診斷腫瘤的重要輔助工具。 | zh_TW |
dc.description.abstract | Magnetic iron oxide (IO) nanoparticles with a long blood retention time, low toxicity, and biodegradability can be engineered to link tumor-targeting ligands for diagnostic imaging. Upregulation of vascular endothelial growth factor (VEGF) is found in many cancer types, which provides an opportunity for designing antibody-targeted approaches for cancer detection and treatment. To determine if the systemic delivery of nanoparticles leads to target specific accumulation into the VEGF-expressing tumor mass in vivo, we injected the VEGF Ab-conjugated IO nanoparticles, which have the superparamagnetic property, through the jugular vein into the balb/c mice bearing colon cancer from the VEGF-positive mouse colon cancer cell line, CT 26. Magnetic resonance imaging (MRI) scan showed the significant decrease of significant T*2 signal and T2 relaxation in the VEGF Ab conjugated IO nanoparticles injected-mice but not in IO nanoparticles-treated mice. Examination of paraffin sections of tumor tissues revealed strong blue reaction obtained from the mice that received VEGF Ab conjugated nanoparticles, but low reaction was found in mice with IO nanoparticles alone injection by Prussian blue staining. A lot of VEGF Ab-conjugated IO nanopartices were present in cells and extracellular matrix in tumor tissues than IO nanoparticle-injected mice by transmission electron microscopy. The present study demonstrated that efficient accumulation of VEGF Ab conjugated IO nanoparticles into tumor cells after systemic delivery. These results suggested that VEGF Ab conjugated IO nanoparticles can be used for the targeted delivery of therapeutic agents. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T17:30:00Z (GMT). No. of bitstreams: 1 ntu-100-R98446005-1.pdf: 4472798 bytes, checksum: 688873107b3ed5032522197afe8a95b2 (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | 中文摘要--------------------------------------------------------------------------------Ⅰ
英文摘要--------------------------------------------------------------------------------Ⅱ 壹、 緒論---------------------------------------------------------------------------------1 一、 大腸癌與腫瘤血管新生-------------------------------------------------1 二、 奈米材料-------------------------------------------------------------------3 三、 奈米粒子在腫瘤診斷及治療上的應用-------------------------------4 四、 奈米粒子對腫瘤組織的標靶作用-------------------------------------6 五、 氧化鐵奈米粒子----------------------------------------------------------7 六、 網狀內皮系統對奈米粒子的清除------------------------------------11 七、 研究動機------------------------------------------------------------------12 貳、 材料與方法----------------------------------------------------------------------13 參、 實驗結果-------------------------------------------------------------------------22 肆、 討論與結論----------------------------------------------------------------------27 伍、 參考文獻-------------------------------------------------------------------------34 陸、 附圖-------------------------------------------------------------------------------45 | |
dc.language.iso | zh-TW | |
dc.title | 血管內皮生長因子抗體鍵結氧化鐵奈米粒子在活體腫瘤中的標靶及造影 | zh_TW |
dc.title | Vascular endothelial growth factor antibody conjugated iron oxide nanoparticles for in vivo tumor targeting and imaging | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 吳造中,王淑美,吳建春,楊謝樂 | |
dc.subject.keyword | 大腸癌,血管內皮細胞生長因子,核磁共振造影,氧化鐵奈米粒子, | zh_TW |
dc.subject.keyword | colon cancer,VEGF,MRI,iron oxide nanoparticles, | en |
dc.relation.page | 56 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2011-07-12 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 解剖學暨生物細胞學研究所 | zh_TW |
顯示於系所單位: | 解剖學暨細胞生物學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 4.37 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。